A1CF and metabolic dysfunction-associated steatohepatitis: In vivo silencing of A1cf via administration of GalNAc-siRNAs reduced lipogenic gene expression and liver steatosis and phenocopied the effects of pharmacologic inhibition of KHK (73, 74), making it a candidate therapeutic target for ameliorating steatosis during NASH progression.